HUE030767T2 - Novel cytostatic 7-deazapurine nucleosides - Google Patents

Novel cytostatic 7-deazapurine nucleosides Download PDF

Info

Publication number
HUE030767T2
HUE030767T2 HUE09702842A HUE09702842A HUE030767T2 HU E030767 T2 HUE030767 T2 HU E030767T2 HU E09702842 A HUE09702842 A HU E09702842A HU E09702842 A HUE09702842 A HU E09702842A HU E030767 T2 HUE030767 T2 HU E030767T2
Authority
HU
Hungary
Prior art keywords
compound
ddd
nmr
mhz
jgem
Prior art date
Application number
HUE09702842A
Other languages
English (en)
Hungarian (hu)
Inventor
Michal Hocek
Petr Naus
Original Assignee
Inst Of Organic Chemistry And Biochemistry Of The Acad Of Sciences Of The Czech Republic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Of Organic Chemistry And Biochemistry Of The Acad Of Sciences Of The Czech Republic filed Critical Inst Of Organic Chemistry And Biochemistry Of The Acad Of Sciences Of The Czech Republic
Publication of HUE030767T2 publication Critical patent/HUE030767T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • H02J7/44—
    • H02J7/485—

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
HUE09702842A 2008-01-18 2009-01-15 Novel cytostatic 7-deazapurine nucleosides HUE030767T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2224708P 2008-01-18 2008-01-18

Publications (1)

Publication Number Publication Date
HUE030767T2 true HUE030767T2 (en) 2017-05-29

Family

ID=40434932

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE09702842A HUE030767T2 (en) 2008-01-18 2009-01-15 Novel cytostatic 7-deazapurine nucleosides
HUE16174985A HUE041598T2 (hu) 2008-01-18 2009-01-15 Újfajta citosztatikus 7-deazapurin nukleozidok

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE16174985A HUE041598T2 (hu) 2008-01-18 2009-01-15 Újfajta citosztatikus 7-deazapurin nukleozidok

Country Status (18)

Country Link
US (1) US8093226B2 (enExample)
EP (2) EP3133080B1 (enExample)
JP (2) JP5485172B2 (enExample)
CN (1) CN101977923B (enExample)
AU (1) AU2009204568B2 (enExample)
CA (1) CA2711384C (enExample)
CY (2) CY1118104T1 (enExample)
DK (2) DK3133080T3 (enExample)
ES (2) ES2598503T3 (enExample)
HR (2) HRP20161344T1 (enExample)
HU (2) HUE030767T2 (enExample)
LT (2) LT3133080T (enExample)
NZ (1) NZ586610A (enExample)
PL (2) PL3133080T3 (enExample)
PT (2) PT3133080T (enExample)
SI (2) SI2231689T1 (enExample)
TR (1) TR201815961T4 (enExample)
WO (1) WO2009089804A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1966202T1 (sl) 2005-12-13 2012-01-31 Incyte Corp S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b)pirimidini kot zaviralci janus kinaze
EP4606378A3 (en) 2007-06-13 2025-11-05 Incyte Holdings Corporation Salts of the janus kinase inhibitor (r)-3-( 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3- cyclopentylprop anenitrile
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
SI2421879T1 (sl) * 2009-04-22 2014-01-31 Institute Of Organic Chemistry And Biochemistry As Cr Novi 7-deazapurinski nukleozidi za terapevtske uporabe
UA106078C2 (uk) 2009-05-22 2014-07-25 Інсайт Корпорейшн 3-[4-(7H-ПІРОЛО[2,3-d]ПІРИМІДИН-4-ІЛ)-1H-ПІРАЗОЛ-1-ІЛ]ОКТАН- АБО ГЕПТАННІТРИЛ ЯК JAK-ІНГІБІТОРИ
AU2010249380B2 (en) 2009-05-22 2015-08-20 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
SI2545045T1 (sl) 2010-03-10 2016-05-31 Incyte Holdings Corporation Derivati piperidin-4-ila kot zaviralci JAK1
MX338228B (es) 2010-05-21 2016-04-08 Incyte Corp Formulacion topica para inhibidor de cinasas janus (jak).
AU2011330730B2 (en) * 2010-11-18 2016-02-18 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
US8933085B2 (en) 2010-11-19 2015-01-13 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
WO2012177606A1 (en) 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
IL297429A (en) 2012-11-15 2022-12-01 Incyte Holdings Corp Sustained release dosage forms of roxolitinib
PT3489239T (pt) 2013-03-06 2021-12-17 Incyte Holdings Corp Processos e intermediários para a preparação de um inibidor de jak
CN114010611B (zh) 2013-08-07 2023-11-28 因赛特控股公司 Jak1抑制剂的持续释放剂型
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2018001393A1 (en) 2016-06-29 2018-01-04 Ustav Organicke Chemie A Biochemie Av Cr, V.V.I. Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use
CZ307334B6 (cs) 2016-08-02 2018-06-13 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Substituované heteropentadieno-pyrrolopyrimidinové ribonukleosidy pro terapeutické použití
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
UA127488C2 (uk) 2018-01-30 2023-09-06 Інсайт Корпорейшн Способи одержання (1-(3-фтор-2-(трифторметил)ізонікотиноїл)піперидин-4-ону)
CZ308104B6 (cs) 2018-03-12 2020-01-08 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. Pyridinopyrrolopyrimidinové ribonukleosidy pro terapeutické použití
PT3773593T (pt) 2018-03-30 2024-06-25 Incyte Corp Tratamento da hidradenite supurativa com inibidores de jak
JP2022527556A (ja) * 2019-04-05 2022-06-02 プレリュード・セラピューティクス・インコーポレイテッド プロテインアルギニンメチルトランスフェラーゼ５の選択的阻害剤
EP3988173A4 (en) * 2019-06-18 2023-08-02 Taiho Pharmaceutical Co., Ltd. NEW PHOSPHORIC ACID ESTER COMPOUND HAVING A PYROLO-PYRIMIDINE SKELETON OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
US20230104311A1 (en) * 2020-02-17 2023-04-06 Katholieke Universiteit Leuven Novel 6-substituted 7-deazapurines and corresponding nucleosides as medicaments
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN112190590A (zh) * 2020-11-06 2021-01-08 牡丹江医学院 一种治疗动脉粥样硬化的硒核苷及其药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50125033A (enExample) * 1974-03-19 1975-10-01
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
JPH10158293A (ja) * 1996-08-08 1998-06-16 Rikagaku Kenkyusho ３’−デオキシリボヌクレオチド誘導体
JP3318579B2 (ja) * 1997-07-07 2002-08-26 理化学研究所 Ｄｎａの塩基配列決定方法
JP3489991B2 (ja) * 1997-07-07 2004-01-26 理化学研究所 ３’−デオキシリボヌクレオチド誘導体
CZ9901996A3 (cs) * 1999-06-04 2001-01-17 Ústav organické chemie a biochemie AV ČR Nové 6-fenylpurinové 9-ß-D-ribonukleosidy s antineoplastickým účinkem, jejich použití k přípravě farmaceutických preparátů a farmaceutické přípravky, které je obsahují
WO2003051899A1 (en) * 2001-12-17 2003-06-26 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
BRPI0414019A (pt) * 2003-08-27 2006-10-24 Biota Inc nucleosìdios ou nucleotìdio tricìclicos como agentes terapêuticos
CN101043893A (zh) * 2004-10-21 2007-09-26 默克公司 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
WO2006065335A2 (en) 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
TW200720285A (en) * 2005-04-25 2007-06-01 Genelabs Tech Inc Nucleoside compounds for treating viral infections

Also Published As

Publication number Publication date
EP3133080A1 (en) 2017-02-22
US8093226B2 (en) 2012-01-10
CA2711384A1 (en) 2009-07-23
PL3133080T3 (pl) 2018-12-31
AU2009204568A1 (en) 2009-07-23
SI3133080T1 (sl) 2018-12-31
ES2598503T3 (es) 2017-01-27
CN101977923A (zh) 2011-02-16
LT2231689T (lt) 2016-10-25
PT2231689T (pt) 2016-10-07
HUE041598T2 (hu) 2019-05-28
JP2014058567A (ja) 2014-04-03
CA2711384C (en) 2016-07-26
JP5485172B2 (ja) 2014-05-07
SI2231689T1 (sl) 2016-11-30
US20090203637A1 (en) 2009-08-13
ES2693551T3 (es) 2018-12-12
EP2231689A1 (en) 2010-09-29
AU2009204568B2 (en) 2013-10-03
PT3133080T (pt) 2018-11-16
WO2009089804A1 (en) 2009-07-23
DK3133080T3 (en) 2018-11-26
HRP20181774T1 (hr) 2018-12-28
DK2231689T3 (en) 2016-09-19
JP2011509949A (ja) 2011-03-31
EP3133080B1 (en) 2018-08-01
NZ586610A (en) 2012-08-31
CN101977923B (zh) 2014-10-08
PL2231689T3 (pl) 2017-01-31
TR201815961T4 (tr) 2018-11-21
EP2231689B1 (en) 2016-07-20
HRP20161344T1 (hr) 2016-11-18
LT3133080T (lt) 2018-11-12
CY1118104T1 (el) 2017-06-28
CY1121364T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
DK3133080T3 (en) PRESENT UNKNOWN CYTOSTATIC 7-DEAZAPURIN NUCLEOSIDES
US10294262B2 (en) 7-deazapurine nucleosides for therapeutic uses
HK1149016B (en) Novel cytostatic 7-deazapurine nucleosides
HK1234411A1 (en) Novel cytostatic 7-deazapurine nucleosides
HK1234411B (en) Novel cytostatic 7-deazapurine nucleosides
HK1166325B (en) Novel 7-deazapurine nucleosides for therapeutic uses